Natural cytotoxicity receptor ligand (NCRL)

Natural cytotoxicity receptor (NCR) ligands are a group of cell-surface molecules that serve as critical triggers for Natural Killer (NK) cell-mediated immunity. These ligands, which include B7-H6 (NCR3LG1), BAG6, and NKp44L (a splice variant of MLL5), are typically upregulated on cells undergoing malignant transformation or viral infection, while remaining largely absent on healthy tissues (Koch et al., 2013). They are recognized by the activating receptors NKp30, NKp44, and NKp46, collectively known as NCRs. Binding of these ligands to their respective receptors induces the formation of an immunological synapse, leading to the release of cytotoxic granules (perforin and granzymes) and pro-inflammatory cytokines like IFN-gamma (Brandt et al., 2009). In oncology, these ligands are being exploited as targets for chimeric antigen receptor (CAR) therapies and multispecific engagers, such as the ANKET (Antibody-based NK cell Engager Therapeutics) platform, which bridges NCRs on NK cells to tumor-associated antigens (Barrow et al., 2018). A significant challenge in targeting this axis is the proteolytic shedding of ligands like B7-H6, which can circulate as soluble decoys that inhibit NK cell activity and facilitate tumor immune evasion.

Other names

NCR ligandsNKp30 ligandNKp44 ligandNKp46 ligandB7-H6NCR3LG1NKp44LMLL5BAG6PDGF-DDBAT3

Facilitation of an immunological synapse between NK cells and target cells by binding to natural cytotoxicity receptors (NKp30, NKp44, or NKp46) or their ligands, triggering NK cell activation and subsequent lysis of the target cell.